Breast Cancer
Conditions
Keywords
circulating tumor DNA
Brief summary
Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy
Detailed description
Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.
Interventions
None listed
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Female patients undergoing NAC * Age: 18-70 yrs * Any menopausal status * Any hormal receptor status
Exclusion criteria
* Metastasis discovered during NAC * Lost more than 2 blood samples during NAC and surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| death of breast cancer | Follow-up time is estimated to be up to 5 years. The duration is from the date of diagnosis to date of death of breast cancer or date of death of any cause, whichever come first. | The event is defined as death of breast cancer, which is a separate measure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| tumor recurrence or distant metastasis | Follow-up time is estimated to be up to 5 years.The duration is from diagnosis to local recurrence or distant metastasis of breast cancer. Patients were followed up every six months in first three years, then followed up once a year. | The event is defined as breast cancer local recurrence or distant metastasis |
Countries
China
Contacts
Primary ContactShunying Li
Outcome results
None listed